DETERMINE precision medicine trial
DETERMINE is the first UK national precision medicine trial in rare cancers
Led by the University of Manchester and sponsored and managed by Cancer Research UK's Centre for Drug Development, DETERMINE is a multi-drug, precision medicine trial for adults, teenagers and children with rare cancers. It is run in collaboration with the University of Birmingham, the Royal Marsden NHS Foundation Trust and the Christie NHS Foundation Trust.
DETERMINE is a trial open in the UK and is expected to recruit until 2027. This trial is exploring whether treatments approved for use in some cancer types can target identifiable genetic alterations in other types. It also provides new treatments options for those who might not have any left.
Drugs which show promising results will be accelerated for Cancer Drug Fund assessment and NHS approval.
Learn more about working with us
For patients
Taking part in the trial is a personal decision. Speak to your doctor if you're interested in participating.
For clinicians
Learn more about patient eligibility, referrals, practicing sites across the UK and treatment arms.
For partners
Find out about the benefits of becoming a commercial partner, meet our team and more.
Meet our investigators
Dr Matthew Krebs
Chief Investigator
University of Manchester
Dr Krebs is a medical oncologist with expertise in precision medicine. He is responsible for the medical, scientific and strategic oversight of the DETERMINE platform. He is also the Chief Investigator of the TARGET Precision Medicine program, which is a major route for patent identification for DETERMINE.
Dr Lynley Marshall
Paediatric Lead
Royal Marsden Hospital
Dr Marshall is a paediatric oncologist with expertise in drug development. She is responsible for overseeing the medical and scientific aspects of the DETERMINE study with respect to children and young people.
Professor Gary Middleton
Translational Lead
University of Birmingham
Professor Middleton is a medical oncologist with expertise in the genomic, transcriptomic and immunological context underlying response to targeted therapy. He is Translational Lead for the DETERMINE study and will coordinate academic research at the Universities of Manchester and Birmingham and the Institute of Cancer Research.
Professor Lucinda Billingham
Statistical Lead
University of Birmingham
Professor Billingham is a biostatistician with an interest in cancer research. She is responsible for the design and statistical analysis of the DETERMINE study.
DETERMINE is an important new trial in the personalised cancer medicine space and provides a crucial opportunity to explore the use of existing medicines in new cancer indications.
— Dr Matthew Krebs, Chief investigator, DETERMINE trial
Meet our partners
University of Manchester
The DETERMINE trial is led and managed by the University of Manchester.
Centre for Drug Development
The DETERMINE trial is sponsored and managed by Cancer Research UK's Centre for Drug Development.
University of Birmingham
The DETERMINE trial is run in collaboration with the University of Birmingham.
The Royal Marsden NHS Foundation Trust
The DETERMINE trial is run in collaboration with the The Royal Marsden NHS Foundation Trust.
Our participant sites
Adult participant sites
England
1. Manchester: The Christie Hospital - Adult - OPEN
2. Birmingham: University Hospital - Adult - OPEN
3. Bristol: Haematology and Oncology Cancer Centre - Adult - OPEN
4. Cambridge: Addenbrookes Hospital - Adult - OPEN
5. Leicester: Leicester Royal Infirmary - Adult - OPEN
6.Liverpool - Adult - OPEN
7. London: Guy's Hospital - Adult - OPEN
8. London: University College London Hospital - Adult - OPEN
9. Newcastle upon Tyne: Freeman Hospital - Adult- OPEN
10. Oxford: Churchill Hospital - Adult - OPEN
11. Sheffield: Weston Park Hospital - Adult - OPEN
12. Southampton - Adult - OPEN
Wales
13. Cardiff: Velindre Cancer Centre - Adult - OPEN
Scotland
14 Edinburgh: Western General Hospital - Adult - OPEN
15. Glasgow: The Beatson Cancer Centre - Adult - OPEN
Northern Ireland
16. Belfast: Health and Social Care Trust - Adult - OPEN
Paediatric participant sites
England
1. London/Surrey: Royal Marsden Hospital - Paediatric, teenagers and young adults - OPEN
2. Bristol: The Bristol Royal Hospital for children - Paediatric, teenagers and young adults - OPEN
3. Cambridge: Addenbrookes Hospital - Paediatric, teenagers and young adults - OPEN
4. Liverpool: Alder Hey - Paediatric, teenagers and young adults - OPEN
5. London: Great Ormond Street Hospital - Paediatric, teenagers and young adults - OPEN
6. Manchester: in set up
7. Newcastle upon Tyne: Great North Children Hospital - Paediatric, teenagers and young adults - OPEN
8. Oxford: John Radcliffe Hospital - Paediatric, teenagers and young adults - OPEN
9. Sheffield: Sheffield Children Hospital - Paediatric, teenagers and young adults - OPEN
Wales
10. Cardiff: in set up
Scotland
11. Glasgow: The Royal Hospital for children Glasgow - Paediatric, teenagers and young adults - OPEN
Northern Ireland
Coming soon
Other things you may be interested in
Our latest news
Discover more about DETERMINE through our latest press releases, articles, awards and network updates.
Find a clinical trial
Visit the Cancer Research UK trial finder to discover useful information and find the right trial for you.
Patient involvement
Insights from people affected by cancer are helping Cancer Research UK beat cancer sooner.